Targets › CCL21
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jan 2027.
Binds to atypical chemokine receptor ACKR4 and mediates the recruitment of beta-arrestin (ARRB1/2) to ACKR4. Binds to chemokine receptor CCR7. (UniProt, O00585)
Open in Phaseline: the race on CCL21, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Jonsson Comprehensive Cancer Center | Autologous Dendritic Cell-Adenovirus CCL21 Vaccine CCL21-gene modified dendritic cell vaccine delivered via adenovirus vector | CCL21 | Phase 1 | Lung Non-Small Cell Carcinoma | Jan 2027 |
Lung Non-Small Cell Carcinoma (1)
mixed (1)
Jonsson Comprehensive Cancer Center (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.